Gotbetter joins the Cedar Knolls-based organization to direct Fingerpaint Market Access, The MYND Group, and BlackPoint Consulting Group. CEO Bill McEllen cited Gotbetter’s comprehensive experience—spanning global payer strategy, real-world evidence, and launch execution—as the primary driver for the hire. The appointment is intended to sharpen the firm's ability to assist clients through complex development phases, from rare disease to gene therapy.

Prior to this role, Gotbetter served as global head of evidence, value, and access at Cytel and held a senior vice president position at Parexel. His background includes commercialization leadership at Biogen and strategy roles at BCG and Health Advances. Beyond his corporate work, Gotbetter maintains an active academic presence as an executive in residence at Cornell University and as a contributor to DIA’s professional journals. He arrives at a time when Fingerpaint Group, recently named the 2026 Med Ad News Network of the Year, looks to solidify its position as a unified commercialization platform for global pharmaceutical companies.